No adverse events reportedSignificant beneficial effects in the NMES group: 6MWTD (23.8%), FMD (73.6%), improvement in quality of life and depression assessed by KCCQ, MLHFQ scores, BDI questionnaires and Zung self-rated depression scores.Placebo group: no change in FMD,A tendency toward a lower mitral E/e’ wave ratio was observed in the NMES groupSignificant difference between groups: FMD, 6MWTD, quality of life and depressionBNP nonsignificant change in plasma BNP levels was observed between both groups. This evidence concerns the gene NPPB and depressive symptom measurement.